Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: G3NEC are heterogeneous and aggressive diseases which can arise in different organs. Platinum-etoposide combination is used as first line treatment whatever the primary. Rb has been suggested to be a predictive/prognostic factor.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Hadoux J
Authors: Hadoux J, Kanaan C, Planchard D, Malka D, Ducreux M,
Keywords: Neuroendocrine carcinoma, Platinum-etoposide, Rb,
#3056 Multi-Omic Characterization and Evolution of Neuroendocrine Neoplasm Organoids
Introduction: Molecular characterizations of neuroendocrine neoplasm (NENs) have unveiled candidate alterations associated with aggressiveness and suggested that the molecular link between neuroendocrine tumors (NETs) and neuroendocrine carcinomas (NECs) might be subtler than initially thought. For example, we have recently unveiled a new entity of pulmonary carcinoids (supra-carcinoids) with carcinoid-like morphology yet the molecular and clinical features of large cell neuroendocrine carcinoma (LCNEC). Testing hypotheses to explain aggressiveness and the possibility of progression or transition from NET to NEC through the accumulation of genetic anomalies requires in vitro and in vivo experimental models.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Foll M
Authors: Alcala N, Dayton T, Mangiante L, Delhomme T, Tabone-Egling S,
Keywords: organoids, omics, evolution, lung, pancreas, bioinformatics,
Introduction: Non-functioning (NF), sporadic pancreatic neuroendocrine tumors (pNETs) have usually an indolent behavior, but sometimes show an unpredictable aggressiveness. Surgery is the first-choice for localized tumors >2 cm. Unresectable or metastatic lesions expressing somatostatin receptors (SSTRs) are treated with Somatostatin analogs (SSAs). No evidence of SSAs efficacy exists in tumors ≤2 cm, for which active surveillance has been proposed.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Schinzari G, Maiorano B, Rossi E, Bianchi A, Chiloiro S,
Keywords: pNET, non-functioning, sporadic, somatostatin analogs, surveillance,
Introduction: Temozolomide (TMZ) and dacarbazine (DTIC) are alkylating agents (ALK) with antitumor efficacy in metastatic PanNET. Rechallenging ALK following prior efficacy is commonly performed but has not been evaluated.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: De Rycke O, Walter T, Perrier M, Hentic O, Lombard-Bohas C,
Keywords: alkylating agents, pancreatic NET, re-challenge, chemotherapy,
#3040 Palliative CT Brachytherapy in Hepatic Metastatic NET
Introduction: Hepatic metastases of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) may induce prognosis relevant complications in an otherwise stable systemic disease after resection of the primary.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Jann H
Authors: Feldhaus F, Jann H, Jonczyk M, Boening G, Wieners G,
Keywords: brachytherapy, afterloading, hepatic metastases, local tumor ablation, local tumor control,